Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.

ABSTRACT:

Background

Interferon-beta (IFNβ) is used to inhibit disease activity in multiple sclerosis (MS), but its mechanisms of action are incompletely understood, individual treatment response varies, and biological markers predicting response to treatment have yet to be identified.

Methods

The relationship between the molecular response to IFNβ and treatment response was determined in 85 patients using a longitudinal design in which treatment effect was categorized by brain magnetic resonance imaging as good (n = 70) or poor response (n = 15). Molecular response was quantified using a customized cDNA macroarray assay for 166 IFN-regulated genes (IRGs).

Results

The molecular response to IFNβ differed significantly between patients in the pattern and number of regulated genes

SUBMITTER: Rudick RA 

PROVIDER: S-EPMC3094352 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature